Natasha Jolakoski on Rethinking Lead-in Strategies in VTE
Natasha Jolakoski, PGY-2 Thrombosis and Hemostasis Resident at The University of New Mexico Hospital, shared on LinkedIn:
”I’m excited to share that our multicenter study, “Rethinking lead-in strategies: evaluation of full vs. reduced-dose factor Xa inhibitors in acute VTE,” has been published in the Journal of Thrombosis and Thrombolysis.
This study evaluated bleeding and thrombotic outcomes associated with reducing factor Xa inhibitor lead-in duration in patients who received prior parenteral anticoagulation, across 1,400+ patients with acute VTE.
We found that a reduced lead-in approach was not associated with higher rates of VTE recurrence or major bleeding.
I’d like to thank my preceptors, Stephanie Edwin and Christopher Giuliano , for their guidance and support throughout this project, as well as all the co-authors who made this collaboration possible.”
Read the full article here.
Article: Rethinking lead-in strategies: evaluation of full vs. reduced dose factor Xa inhibitors in acute VTE
Authors: Natasha Jolakoski, Sarah Grazia, Clare Brewster, Brehanna Edwards, Danielle Rosas, Diana Penev, Whitney Anderson, Stephanie B. Edwin, Shannon Carabetta, Bradley Haan, Thomas Breedan, Megan Laux, Kathaleen Watson, Andrew Harpenau, Rachel Bruns, Josephine Varda, Kathleen Koopman, Meagan Paylor, Christopher Guiliano
Stay updated on all scientific advances with Hemostasis Today.
-
Dec 13, 2025, 17:38Amaliris Guerra: Science We Do Has Real Human Stakes
-
Dec 13, 2025, 17:20James Morrissey Shares the Explanation of A Literally 30 Years Worth of TF Biochemistry
-
Dec 13, 2025, 17:03Danny Hsu: Aspirin May Prevent Cancer Metastases?
-
Dec 13, 2025, 16:33Ana Cláudia de Souza: Opening Event for ÁRTEMIS-Brasil, a PROADI-SUS Project
-
Dec 13, 2025, 16:19Chandra Viswanathan on Altruism and Donating Blood
-
Dec 13, 2025, 16:09Brehanna Edwards Compares Apixaban or Rivaroxaban in VTE
-
Dec 13, 2025, 15:36Jeyaraj Pandian’s Visit to China to Support Advancement and Standardization of Stroke Care
-
Dec 13, 2025, 15:20An Important Step Forward in ITP: Shreeram Aradhye Shares Ianalumab Phase III Results!
-
Dec 12, 2025, 23:51Don’t Miss: IACH Post ASH 2025 Roundtable Debate